Nuclear medicine firm Curium Pharma has announced plans to implement a new pricing model for Technescan MAG3, a kit for preparing technetium-99m (Tc-99m) mertiatide.
Curium is transitioning to a pay-per-vial model for Technescan MAG3 and phasing out its pay-per-dose approach, the company said. The renal imaging agent is intended for use in diagnosing congenital and acquired abnormalities, renal failure, urinary tract obstruction. and calculi in adults and pediatric patients.
Under the new pricing policy, the average price per vial will be approximately $625 for most U.S. customers, according to Curium.
